<DOC>
	<DOCNO>NCT02634424</DOCNO>
	<brief_summary>The purpose study evaluate implementation pharmacokinetic ( PK ) drive prophylaxis current clinical practice</brief_summary>
	<brief_title>PK Driven Prophylaxis Hemophilia A</brief_title>
	<detailed_description>Starting 3 pharmacokinetic ( PK ) point , data enter PK calculator device , treatment dose adjust follow result PK value obtain clinical bleeding data</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Male Patient Severe moderately severe haemophilia A ( FVIII = 2 % ) , preventively treat ( process ) ADVATE least 6 month , At last 6 year old , An informed consent must sign patient legal representative patient minor . Affiliated national insurance scheme Previous actual treatment FVIII inhibitor &gt; 0,6 UB selection Induction immune tolerance Planned orthopedic surgery 18 next month Any haemostatic pathology Any treatment interact haemostasis Patient guardianship Patient participate another biomedical research</criteria>
	<gender>Male</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Hemophilia A</keyword>
	<keyword>Prophylaxy</keyword>
	<keyword>Pharmacokinetic</keyword>
	<keyword>Bayesian</keyword>
</DOC>